Amryt Pharma plc

Based in Ireland, Amryt Pharma plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for rare and debilitating conditions, aiming to enhance patient quality of life through specialized treatments. Amryt Pharma plc is engaged in the development of therapies aimed at rare diseases. Founded in 2015 and headquartered in Dublin, Ireland, the company has undergone strategic pivots to focus on niche markets in rare diseases. Raj K serves as the CEO.

The firm has completed 1 deal, with the most recent one dated February 18, 2022. Amryt Pharma specializes in innovative therapies for rare and debilitating conditions. Its key products include Juxtapid® (Lojuxta®) for homozygous familial hypercholesterolemia, Myalept® (Myalepta®) for lipodystrophy, and Mycapssa® for acromegaly management. These products cater to healthcare professionals and institutions across the United States, Europe, and select markets in Asia and Latin America, aimed at improving the quality of life for patients.

In the year 2021, Amryt Pharma reported a revenue of USD 222. 54 mn and an EBITDA of USD 16. 57 mn. The company's revenue is primarily generated through sales of its specialized pharmaceutical products to healthcare providers and institutions, with transactions occurring through direct sales and partnerships with distributors.

Amryt Pharma is focused on expanding its product portfolio and entering new markets. The company is anticipated to launch additional therapies in the coming years to address unmet medical needs in rare conditions. Recent funding will support these initiatives and enhance their market reach, with plans for expansion into additional regions including Asia. The most recent deal dated February 18, 2022, is expected to facilitate these growth strategies.